Nyrada Doses First Patient in Heart Attack Trial With Results Due Late 2027
First patient dosed as Nyrada’s PROTECT-MI Phase IIa trial gets underway
Nyrada Inc (ASX:NYR) has confirmed that the first patient has been dosed in its PROTECT-MI Phase IIa clinical trial for lead candidate Xolatryp®. The trial is designed to assess the safety and preliminary efficacy of Xolatryp® in reducing heart tissue damage and improving heart function in patients suffering a heart attack.
It is structured as a randomised, double-blind, placebo-controlled study. The dosing milestone marks the transition of the programme into active Phase IIa patient recruitment.
When big ASX news breaks, our subscribers know first
A key clinical milestone reached
Nyrada confirmed the first patient in its Phase IIa clinical trial has been dosed. The patient will be followed for a further 30 days for safety and tolerability outcomes, as well as efficacy measures.
Because the trial is a randomised, double-blind, placebo-controlled study, it is not known whether this first patient received Xolatryp® or a placebo.
Efficacy data will not be available until study completion, when the trial data is unblinded. No efficacy conclusions can be drawn from this dosing milestone. Nyrada will provide periodic updates on participant recruitment and Safety Review Committee (SRC) assessments as the study progresses.
Milestone highlight
First patient dosed in Nyrada’s PROTECT-MI Phase IIa Clinical Trial, marking the commencement of active dosing in the study.
Trial sites expanding across Australia and into New Zealand
Site activation is advancing across multiple locations, with recruitment capacity expected to build over the coming period. The current status of the trial network is as follows:
-
Sir Charles Gairdner Hospital, Perth, described as one of Western Australia’s largest tertiary cardiac centres, is expected to be activated this week, enabling patient recruitment.
-
Research governance office (RGO) approval for other selected sites in Australia is advancing.
-
Nyrada is progressing expansion of the study into New Zealand.
Nyrada actively monitors recruitment performance across all trial sites. Subject to local RGO approvals, the company retains the flexibility to bring on additional sites and concentrate resources where recruitment potential is strongest.
What is Xolatryp® and why TRPC ion channels matter
Nyrada is a clinical-stage biotechnology company focused on developing Transient Receptor Potential Canonical (TRPC) ion channel inhibitors to treat a range of medical conditions.
The PROTECT-MI trial assesses Xolatryp® in reducing cardiac reperfusion injury in patients with ST-Elevation Myocardial Infarction (STEMI) undergoing PCI. Limiting this damage is clinically significant because it may help preserve heart function and improve patient outcomes.
Ischemia-reperfusion injury in STEMI is the mechanism Xolatryp targets: the paradoxical tissue damage that occurs when blood flow is restored to the heart following a blockage, a process for which no approved therapies currently exist despite affecting millions of PCI patients each year.
Xolatryp® has shown efficacy in preclinical cardioprotection, neuroprotection and oncology models, and has completed a first-in-human Phase I clinical trial.
Timelines and what comes next
Nyrada anticipates that the final patient will be dosed in mid-2027. Top-line results are anticipated approximately three months following the final patient’s 30-day follow-up visit.
The company will continue to update the market on site activations, recruitment progress and other material developments as the trial advances. Further information is available at the U.S. National Library of Medicine clinical trial registry (NCT07362446) and the PROTECT-MI website.
| Milestone | Status / Timing |
|---|---|
| First patient dosed | Achieved (Jul 2026) |
| Sir Charles Gairdner Hospital activation | Expected this week |
| Additional Australian sites | RGO approval advancing |
| New Zealand expansion | Progressing |
| Final patient dosed | Mid-2027 |
| Top-line results | ~3 months after final patient 30-day follow-up |
The next major ASX story will hit our subscribers first
The investment angle
Reaching the first-patient-dosed milestone moves Xolatryp® from a preparation phase into active Phase IIa dosing. The multi-site, multi-jurisdiction strategy spanning Australia and New Zealand is designed to support recruitment momentum, with the company retaining flexibility to concentrate resources where recruitment potential is strongest.
Xolatryp®’s preclinical results span cardioprotection, neuroprotection and oncology models.
Investors should note that efficacy remains unproven until the trial is unblinded at study completion. This update represents a progress milestone in trial execution, not a results readout.
For investors exploring the breadth of Xolatryp’s pipeline beyond the STEMI indication, our detailed coverage of the cardiomyopathy pilot study walks through the preclinical troponin data, the subcutaneous dosing findings, and what the larger follow-on study design means for Nyrada’s cardioprotection programme.
Don’t Miss the Next ASX Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers who stay ahead of the market the moment announcements drop. Click the “Free Alerts” button at Big News Blast to get started today.